New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

BioCardia, Inc. (BCDA) vs Passage Bio, Inc. (PASG)

BioCardia, Inc. and Passage Bio, Inc. are both Biotechnology companies. BioCardia, Inc. and Passage Bio, Inc. are of similar size ($11.7M and $11.6M). Across the 8 metrics below, BioCardia, Inc. leads on 6 and Passage Bio, Inc. on 2.

Valuation

Metric BCDA PASG Biotechnology median
P/E n/m n/m 8.49
P/S 26.88 — 8.56
P/B 13.78 253.58 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.21 0.69
EV/Sales 21.68 — 8.00
Earnings yield (84.95%) (262.60%) (35.81%)
Free cash flow yield (66.25%) (257.29%) (25.41%)

Profitability

Metric BCDA PASG Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (2,010.75%) — 0.00%
Net margin (1,999.77%) — 0.00%
Free cash flow margin — — 0.00%
Return on equity (443.27%) (212.27%) (51.58%)
Return on assets (166.46%) (69.68%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCDA PASG Biotechnology median
Revenue growth (TTM) 0.71% — 7.20%
EPS growth (last fiscal year) 57.59% 32.94% 29.04%
Revenue growth, 5-year CAGR 26.89% — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric BCDA PASG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.11 1.00 4.79
Net debt to EBITDA 0.30 0.96 1.01

Dividend

Metric BCDA PASG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCDA PASG Biotechnology median
Market cap 11.70m 11.62m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack